Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197870 | 0.93 | MCHR1 (0.45) | EPHX2MCHR1KDM4ETDP1ABL1 | |
| SCHEMBL13197898 | 0.89 | TP53 (0.44) | EPHX2MCHR1IGF1RKDM4ETDP1 | |
| SCHEMBL13197911 | 0.89 | MCHR1 (0.45) | EPHX2MCHR1KDM4ETDP1ABL1 | |
| SCHEMBL13197880 | 0.88 | EPHX2 (0.43) | EPHX2MCHR1IGF1RKCNA5ABL1 | |
| SCHEMBL13197820 | 0.88 | EPHX2 (0.46) | EPHX2MCHR1IGF1RKCNA5ABL1 | |
| SCHEMBL13197884 | 0.85 | MCHR1 (0.43) | EPHX2MCHR1IGF1RKCNA5 | |
| SCHEMBL13197861 | 0.85 | MCHR1 (0.43) | EPHX2MCHR1KDM4ETDP1ALDH1A1 | |
| SCHEMBL13197821 | 0.85 | NAMPT (0.51) | EPHX2KDM4EALDH1A1 | |
| SCHEMBL13197881 | 0.85 | EPHX2 (0.44) | EPHX2MCHR1IGF1RKCNA5SCN9A | |
| SCHEMBL13197819 | 0.85 | PPARA (0.46) | EPHX2IGF1RPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | EPHX2 3922/4885MCHR1 4719/4885IGF1R 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.